



Inotrem expands its Leadership Team with the appointment of Delphine Joyeux as Director of Regulatory Affairs and Quality Assurance and of Simon Lambden as Head of Medical Science

Paris, September 25th, 2020. Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway, announced today the appointment of Delphine Joyeux as Director of Regulatory Affairs and Quality Assurance and Simon Lambden as Head of Medical Science.

Delphine Joyeux brings 20 years of leadership experience in worldwide Regulatory Affairs and Product Development with a global vision across all disciplines of product development. She will report to Chief Development Officer, Margarita Salcedo-Magguilli. Through this newly created position, Delphine will be responsible for developing and implementing the firm's regulatory strategies. She will also be in charge of implementing and supervising quality management for the firm. Before joining Inotrem, Delphine was Head of Regulatory Affairs at AB Science. She started her career at Boehringer-Ingelheim, and over the years served both in large global pharmaceutical companies such as Laboratoires Servier, Pfizer and Onxeo. Delphine graduated in 1997 from the School of Pharmacy Paris Sud.

Simon Lambden brings extensive experience in the field of clinical and academic Intensive Care and Internal Medicine. He has completed specialist training in anaesthesia and intensive care alongside which his doctoral and postdoctoral research explored the mechanisms underlying critical illness, work for which he has secured a number of prizes. Simon will report to Dr. Jean-Jacques Garaud, CEO of Inotrem. Through this newly created position, Simon will be responsible for the medical supervision of all ongoing and future clinical research activities at Inotrem. He will also be the safety officer for the products portfolio. Simon is a Clinical Research Associate in Intensive Care Medicine at the University of Cambridge, and an Honorary Consultant in Intensive Care Medicine at Cambridge University Hospitals NHS Foundation Trust.

"We are thrilled to welcome such talented individuals in our leadership team and look forward to their guidance and contributions as we advance our immunotherapy products pipeline. We started collaborating with Simon during Inotrem's Covid-19 Phase II clinical trial that was launched a few weeks ago and are excited to have him onboard as we are accelerating our development. Delphine has successfully spearheaded regulatory and quality efforts in a number of global biopharmaceutical companies, where she managed European and US clinical trial applications, INDs and marketing authorizations, and will bring great value to the team", declares Jean-Jacques Garaud, CEO of Inotrem.

About Inotrem

Inotrem S.A. is a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, LR12 (nangibotide), with potential applications in a number of therapeutic indications such as septic shock. In parallel, Inotrem has also launched another program to develop a new therapeutic modality targeting chronic inflammatory diseases. The company was founded in 2013 by Dr. Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sébastien Gibot and Dr. Marc Derive. Inotrem is supported by leading European and North American investors. Inotrem belongs to the French Tech 120 program which has been set up by the French President and the Prime Minister to support the development of start-ups with top growth potential.

www.inotrem.com



Media contact for Inotrem

Anne REIN

Strategies & Image (S&I)

anne.rein@strategiesimage.com

+33 6 03 35 92 05